

Rule
1.126

APC
3/14/02

29 ~~27~~

A method for the treatment of a T cell-mediated or T cell-dependent autoimmune disease by suppressing an autoimmune response associated with said disease in a human suffering from said autoimmune disease, said method comprising orally or enterally administering to said human at least one antigen in an amount effective to suppress said autoimmune response, said antigen selected from the group consisting of autoantigens specific for said autoimmune disease, said suppression comprising elicitation of suppressor T cells specific to said administered antigen.



30 ~~28~~

The method of claim 27, wherein said treatment suppresses the symptoms of said autoimmune diseases in said human.

31 ~~29~~

The method of claim 27 wherein said autoantigen is administered orally.

32 ~~30~~

The method of claim 27 wherein said autoantigen is administered enterally.

33 ~~31~~

The method of claim 27 wherein said autoimmune disease is multiple sclerosis.

34 ~~32~~

The method of claim 27 wherein said autoantigen is myelin basic

protein (MBP).

Sub 3
~~35~~ 33. A method of treating a T cell-mediated or T cell-dependent autoimmune disease by suppressing an autoimmune response associated with said disease in a human suffering from said autoimmune disease, said method comprising orally or enterally administering to said human at least one antigen in an amount effective to suppress said autoimmune response said antigen selected from the group consisting of autoantigens specific for said autoimmune disease.

Sub 34
~~36~~ 34. The method of claim ~~33~~ wherein said autoantigen is myelin basic protein (MBP).

J Sub 35
~~37~~ 35. The method of claim 33 wherein said autoantigen is bovine myelin basic protein.

~~38~~ 36. The method of claim 27 wherein said autoantigen is contained in tissue that is the site of attack in the autoimmune disease.

~~39~~ 37. The method of claim ~~32~~ wherein said autoantigen is contained in tissue that is the site of attack in the autoimmune disease.

~~40~~ 38. The method of claim 33 wherein said autoantigen is contained in tissue that is the site of attack in the autoimmune disease.

~~41~~ 39. The method of claim ~~35~~ wherein said autoantigen is contained in tissue that is the site of attack in the autoimmune disease.